<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="table1-2049936120947517" orientation="portrait" position="float">
 <label>Table 1.</label>
 <caption>
  <p>Summary of 
   <italic>in vitro</italic> and 
   <italic>in vivo</italic> studies of the use of CQ/HCQ in COVID-19.
  </p>
 </caption>
 <alternatives>
  <graphic xlink:href="10.1177_2049936120947517-table1" xmlns:xlink="http://www.w3.org/1999/xlink"/>
  <table frame="hsides" rules="groups">
   <colgroup span="1">
    <col align="left" span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
    <col align="char" char="." span="1"/>
   </colgroup>
   <thead>
    <tr>
     <th align="left" rowspan="1" colspan="1">Study</th>
     <th align="left" rowspan="1" colspan="1">Study type</th>
     <th align="left" rowspan="1" colspan="1">Objective</th>
     <th align="left" rowspan="1" colspan="1">Outcome</th>
     <th align="left" rowspan="1" colspan="1">Result/s</th>
     <th align="left" rowspan="1" colspan="1">Conclusion</th>
    </tr>
   </thead>
   <tbody>
    <tr>
     <td rowspan="1" colspan="1">Wang 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr35-2049936120947517" ref-type="bibr">35</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">
      <italic>In vitro</italic>
     </td>
     <td rowspan="1" colspan="1">To evaluate antiviral efficiency of ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine, remdesivir and favipiravir against 
      <italic>in vitro</italic> SARS-CoV 2
     </td>
     <td rowspan="1" colspan="1">Drug efficacy was quantified 
      <italic>via</italic> viral numbers in cell supernatant (qRT-PCR) and viral nucleoprotein expression (immunofluorescence microscopy)
     </td>
     <td rowspan="1" colspan="1">CQ blocked the virus at low concentrations during both entry and post-entry phases of cellular infection</td>
     <td rowspan="1" colspan="1">CQ has potential for clinical use against the SARS-CoV 2 due to potent blocking viral infection demonstrating its antiviral effects, however, 
      <italic>in vivo</italic> studies are warranted
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Yao 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr36-2049936120947517" ref-type="bibr">36</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">
      <italic>In vitro</italic>
     </td>
     <td rowspan="1" colspan="1">To test CQ/HCQ 
      <italic>in vitro</italic> activity against SARS-CoV 2 infected Vero cells
     </td>
     <td rowspan="1" colspan="1">Drug efficacy was quantified using the detection of viral RNA 
      <italic>via</italic> RT-PCR
     </td>
     <td rowspan="1" colspan="1">A twice-daily HCQ (loading dose of 400 mg and maintenance dose of 200 mg) for four days achieved three times the potency of the standard 500 mg CQ given in advance for five days</td>
     <td rowspan="1" colspan="1">HCQ has higher potency than CQ in inhibiting SARS-CoV 2 
      <italic>in vitro</italic>
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Chen 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr37-2049936120947517" ref-type="bibr">37</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Pilot</td>
     <td rowspan="1" colspan="1">To evaluate HCQ against COVID-19</td>
     <td rowspan="1" colspan="1">Negative SARS-CoV 2 nucleic acid conversion rate 
      <italic>via</italic> respiratory pharyngeal swab
     </td>
     <td rowspan="1" colspan="1">More patients in the control group achieved a higher negative pharyngeal swab of viral nucleic acid at 7 days (93.3%, 
      <italic>n</italic> = 14 
      <italic>versus</italic> 86.7%, 
      <italic>n</italic> = 13, 
      <italic>p</italic> &gt; 0.05).
     </td>
     <td rowspan="1" colspan="1">Although HCQ showed good prognosis in moderate COVID-19 infection, further investigation is needed with larger sample sizes and better endpoints</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Gautret 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr38-2049936120947517" ref-type="bibr">38</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Open-label non-randomised clinical trial</td>
     <td rowspan="1" colspan="1">To evaluate HCQ against COVID-19 
      <italic>via</italic> respiratory viral load
     </td>
     <td rowspan="1" colspan="1">Post-inclusion virus presence and/or absence</td>
     <td rowspan="1" colspan="1">Higher viral clearance in the HCQ group (200 mg thrice-daily) compared with the control (70% 
      <italic>versus</italic> 12.5%, 
      <italic>p</italic> = 0.001). HCQ + azithromycin showed 100% viral clearance at the same time, while HCQ only had 57.1% and control group 12.5% (
      <italic>p</italic> &lt; 0.001)
     </td>
     <td rowspan="1" colspan="1">HCQ resulted in reduced or absent viral load</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Molina 
      <italic>et al</italic>.
      <sup>
       <xref rid="bibr39-2049936120947517" ref-type="bibr">39</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Prospective study</td>
     <td rowspan="1" colspan="1">To assess HCQ + azithromycin antiviral properties against COVID.</td>
     <td rowspan="1" colspan="1">Viral detection 
      <italic>via</italic> nasopharyngeal swabs 
      <italic>via</italic> PCR assay
     </td>
     <td rowspan="1" colspan="1">Positive SARS-CoV 2 nucleic acids in 8 of the 10 patients, while one patient died.</td>
     <td rowspan="1" colspan="1">No substantial evidence on HCQ + azithromycin in severe COVID-19 patients</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Chen 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr40-2049936120947517" ref-type="bibr">40</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Randomised clinical trial</td>
     <td rowspan="1" colspan="1">To evaluate HCQ efficacy against COVID-19</td>
     <td rowspan="1" colspan="1">Time to clinical recovery, clinical characteristics, radiological results occurring 5 days following study enrollment, or severe adverse effects</td>
     <td rowspan="1" colspan="1">Shortened time to clinical recovery in the HCQ group and a higher degree of improvement in pneumonia than the control (80.6% 
      <italic>versus</italic> 54.8%)
     </td>
     <td rowspan="1" colspan="1">HCQ showed significant shortening of time to clinical recovery and promotion of pneumonia absorption</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Mahévas 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr41-2049936120947517" ref-type="bibr">41</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Clinical trial</td>
     <td rowspan="1" colspan="1">To assess the clinical efficacy of oral HCQ (600 mg)</td>
     <td rowspan="1" colspan="1">ICU transfer and death from any cause</td>
     <td rowspan="1" colspan="1">In total, 20.2% of patients receiving HCQ ended up in the ICU or had died within 1–7 days compared with 22.1% without HCQ (16 
      <italic>versus</italic> 21 adverse events; RR 0.91; 95% CI: 0.47–1.80)
     </td>
     <td rowspan="1" colspan="1">Results do not support HCQ use in COVID-19 patients as no significant reduction in ICU admission, death, or ARDS occurred</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Borba 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr42-2049936120947517" ref-type="bibr">42</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Randomised clinical trial (preliminary Results)</td>
     <td rowspan="1" colspan="1">A comprehensive evaluation of CQ safety and efficacy against COVID-9</td>
     <td rowspan="1" colspan="1">Mortality by day-28</td>
     <td rowspan="1" colspan="1">High fatality rates (27%, 95% CI: 17.9–38.2%) with high dose CQ (600 mg twice daily or 12 g total) than the low dose (450 mg daily or 2.7 g total).
      <break/>More QTc and higher lethality in the high CQ dose (18.9% and 39%)
     </td>
     <td rowspan="1" colspan="1">High CQ dose is not advised for use in COVID-19 due to safety risks</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Magagnoli 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr43-2049936120947517" ref-type="bibr">43</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Retrospective Study</td>
     <td rowspan="1" colspan="1">To assess HCQ, either alone or in combination with azithromycin, against COVID-19</td>
     <td rowspan="1" colspan="1">Hospitalisation (discharge/death), requirement of ventilation, patient status following ventilation in hospitalised patients</td>
     <td rowspan="1" colspan="1">Death rate in HCQ, HCQ + azithromycin, and non-HCQ groups were 27.8%, 22.1%, 11.4%, respectively.
      <break/>Significantly high risk of death in HCQ groups (adjusted HR 2.61, 95% CI 1.10–6.17, 
      <italic>p</italic> = 0.03); but it was non-significant HCQ + azithromycin groups (adjusted HR 1.14, 95% CI 0.56–2.32; 
      <italic>p</italic> = 0.72)
     </td>
     <td rowspan="1" colspan="1">No evidence that HCQ (+azithromycin) decreased the risk of mechanical ventilation in COVID-19 hospitalised patients</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Saleh 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr44-2049936120947517" ref-type="bibr">44</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Prospective observational safety study</td>
     <td rowspan="1" colspan="1">To evaluate CQ, HCQ, and azithromycin in association with QT interval, Torsade de Pointes risk and sudden cardiac death in COVID-19</td>
     <td rowspan="1" colspan="1">QT prolongation leading to Torsade de Pointes</td>
     <td rowspan="1" colspan="1">No TdP or sudden death due to arrhythmia was noted. These medications did prolong the QT interval but did not lead to the discontinuation of therapy</td>
     <td rowspan="1" colspan="1">Although there were no TdP or sudden death due to arrhythmia, more studies are needed for the conclusive results</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">van den Broek 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr45-2049936120947517" ref-type="bibr">45</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Retrospective Observational cohort safety study</td>
     <td rowspan="1" colspan="1">To evaluate CQ-induced CTc prolongation among COVID-19 patients</td>
     <td rowspan="1" colspan="1">QTc prolongation 
      <italic>via</italic> ECG recording
     </td>
     <td rowspan="1" colspan="1">Mean QTc prolongation of CQ: 35 ms (95% CI 28–43 ms) with computerised and 34 ms (95% CI 25–43 ms) with manual interpretation, respectively</td>
     <td rowspan="1" colspan="1">CQ significantly prolonged QTc interval emphasizing the need for patient monitoring and caution with its use</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Mercuro 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr46-2049936120947517" ref-type="bibr">46</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Observational cohort study</td>
     <td rowspan="1" colspan="1">To identify risk/degree of QT prolongation by HCQ +/– azithromycin in COVID-19 patients</td>
     <td rowspan="1" colspan="1">QT interval change</td>
     <td rowspan="1" colspan="1">HCQ + azithromycin had a greater median change in QT interval than HCQ alone (23 msec 
      <italic>versus</italic> 5.5 msec 
      <italic>p</italic> = 0.03)
     </td>
     <td rowspan="1" colspan="1">HCQ use both alone or with azithromycin was associated with an elevated risk of QTc prolongation</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Jain 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr47-2049936120947517" ref-type="bibr">47</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Safety study</td>
     <td rowspan="1" colspan="1">To improve ECG monitoring of COVID-19 patients</td>
     <td rowspan="1" colspan="1">QT prolongation 
      <italic>via</italic> ECG monitoring and SBAR tool (situation background assessment recommendation)
     </td>
     <td rowspan="1" colspan="1">SBAR efficiently identified QT prolongation, with 95.1% being related to QT-prolonging medications.</td>
     <td rowspan="1" colspan="1">A high percentage of QT prolongation was identified using SBAR leading to earlier intervention</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Geleris 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr48-2049936120947517" ref-type="bibr">48</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Observational study</td>
     <td rowspan="1" colspan="1">To examine the association between HCQ and risk of intubation/death in COVID-19 patients.</td>
     <td rowspan="1" colspan="1">Intubation, dead, or discharge within 24 hrs of ER presentation.</td>
     <td rowspan="1" colspan="1">No significant association of HCQ with lowering the risk of intubation or death (HR 1.04; 95% CI 0.82–1.32)</td>
     <td rowspan="1" colspan="1">HCQ did not show lowered/increased risk of intubation or death. Further studies are needed on HCQ 
      <italic>via</italic> RCT
     </td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Tang 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr49-2049936120947517" ref-type="bibr">49</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Open-label randomised controlled trial</td>
     <td rowspan="1" colspan="1">To assess HCQ efficacy and safety profile in COVID-19 patients.</td>
     <td rowspan="1" colspan="1">Negative virus conversion</td>
     <td rowspan="1" colspan="1">The probability of negative viral conversion was similar in the HCQ (85.4%, 95% CI: 71.8–93.8) and control (81.3%, 95% CI: 71.2– 89.6). But, adverse events were higher in HCQ (30% 
      <italic>versus</italic> 8.8%)
     </td>
     <td rowspan="1" colspan="1">HCQ did not increase negative viral conversion; however, higher rates of adverse events were noted with HCQ</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Rosenberg 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr50-2049936120947517" ref-type="bibr">50</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Retrospective multicentre cohort study</td>
     <td rowspan="1" colspan="1">To describe the association between HCQ, either alone or in combination with azithromucin, and clinical outcome among hospitalised COVID-19 patients</td>
     <td rowspan="1" colspan="1">In-hospital mortality</td>
     <td rowspan="1" colspan="1">No significant association between HCQ and a reduction or increased mortality rate due to COVID-19 complications (HR 1.08; 95% CI: 0.63–1.85)</td>
     <td rowspan="1" colspan="1">The majority of the observed fatalities are attributed to coexisting clinical comorbidities, like hypertension, obesity, diabetes mellitus, liver, or kidney dysfunction</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Boulware 
      <italic>et al.</italic>
      <sup>
       <xref rid="bibr51-2049936120947517" ref-type="bibr">51</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Double-blind randomised controlled trial</td>
     <td rowspan="1" colspan="1">To assess post-exposure prophylaxis with
      <break/>HCQ after SARS-CoV 2 exposure.
     </td>
     <td rowspan="1" colspan="1">Laboratory-confirmed COVID-19, or COVID-19 like illness within 14 days</td>
     <td rowspan="1" colspan="1">No significant difference between the HCQ group and placebo (11.8% 
      <italic>versus</italic> 14.3%, absolute difference -2.4 percentage points; 95% CI: –7.0 to 2.2; 
      <italic>p</italic> = 0.35), although a higher side effect profile was observed with HCQ than placebo (40.2% 
      <italic>versus</italic> 16.8%)
     </td>
     <td rowspan="1" colspan="1">HCQ did not prevent COVID-19 or illness compatible with COVID-19 following risk exposure. HCQ is not recommended to be used as a post-exposure prophylaxis in COVID-19.</td>
    </tr>
    <tr>
     <td rowspan="1" colspan="1">Randomised Evaluation of COVID-19 therapy (RECOVERY) trial
      <sup>
       <xref rid="bibr52-2049936120947517" ref-type="bibr">52</xref>
      </sup>
     </td>
     <td rowspan="1" colspan="1">Open-labeled clinical trial</td>
     <td rowspan="1" colspan="1">To evaluate whether treatment with either Lopinavir-Ritonavir, HCQ, Corticosteroids, Azithromycin, Convalescent plasma or Tocilizumab prevents death in COVID-19 patients</td>
     <td rowspan="1" colspan="1">All-cause mortality Time - within 28 days following randomisation</td>
     <td rowspan="1" colspan="1">No significant difference was observed in the primary outcome of all-cause mortality within 28 days (25.7% 
      <italic>versus</italic> 23.5%, HR 1.11, 95% CI: 0.98–1.26; 
      <italic>p</italic> = 0.10)
     </td>
     <td rowspan="1" colspan="1">No mortality benefit with HCQ in COVID-19 patients, leading to the stoppage of any further participants’ enrollment in the HCQ arm.</td>
    </tr>
   </tbody>
  </table>
 </alternatives>
 <table-wrap-foot>
  <fn id="table-fn1-2049936120947517">
   <p>ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; CQ, chloroquine; HCQ, hydroxychloroquine; HR, hazard ratio; ICU, intensive care unit; RR, relative risk; RT-PCR, reverse transcriptase polymerase chain reaction; SARS-CoV 2, severe acute respiratory syndrome coronavirus 2.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
